secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOLARGO, INC. (BLGO)
CIK:        0000880242
Form:       8-K
Filed at:   2024-11-15T23:59:59+00:00
Accession:  0001437749-24-035426
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioLargo Q3: YTD revenue up 80% to $14.1M; net loss narrows
-----------------------------------------------------------

- Year-to-date revenue $14.1M, up 80% YoY; Q3 revenue $4.4M, up 63% YoY.
- Net loss narrowed to $1.1M in Q3 (from $1.5M) and $2.6M YTD (from $3.6M).
- Current assets $7.4M, cash $3.9M; stockholders' equity $6.0M as of Sept 30, 2024.
- CEO says tenth consecutive year of record revenue; expects 2025 to be another record.
- Investing in production for national rollout of Clyra Medical Technologies products.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/880242/000143774924035426/0001437749-24-035426-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/880242/000143774924035426/blgo20241114_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-035426

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer